[Regulation of bone remodeling by anti-resorptives.]

Classical anti-resorptives such as bisphosphonates inhibit remodeling, leading to decreases in both bone resorption and formation markers. Changes in these markers are useful in predicting future bone mineral density and fracture risk to some extent. More recently developed drugs such as denosumab and odanacatib, which also fall into the category of anti-resorptives, show unique effects on modeling and remodeling. This overview summarizes action of anti-resorptives from a viewpoint of remodeling.